Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease
US9840710B2 · kind B2 · utility
5Cited by
18References
14Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 11, 2016 |
| Grant date | Dec 12, 2017 |
| Priority date | — |
| Expiry date | Nov 11, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/33
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present disclosure relates generally to compounds comprising oligonucleotides complementary to a Leucine-Rich-Repeat-Kinase (LRRK2) RNA transcript. Certain such compounds are useful for hybridizing to a LRRK2 RNA transcript, including but not limited to a LRRK2 RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRRK2 transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Parkinson's disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.